CA2498225A1 - Facteurs de liaison a des toxines bacteriennes - Google Patents

Facteurs de liaison a des toxines bacteriennes Download PDF

Info

Publication number
CA2498225A1
CA2498225A1 CA002498225A CA2498225A CA2498225A1 CA 2498225 A1 CA2498225 A1 CA 2498225A1 CA 002498225 A CA002498225 A CA 002498225A CA 2498225 A CA2498225 A CA 2498225A CA 2498225 A1 CA2498225 A1 CA 2498225A1
Authority
CA
Canada
Prior art keywords
stx
hop bract
tannin
polycatechin
hbt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002498225A
Other languages
English (en)
Inventor
Joel Moss
Masatoshi Noda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiba University NUC
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2498225A1 publication Critical patent/CA2498225A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention a trait à des procédés de neutralisation de toxines bactériennes telles que des toxines Shiga et des toxines de choléra. Dans un mode de réalisation particulier, l'invention a trait à un procédé destiné au traitement d'un sujet souffrant d'une infection provoquée par un organisme de production de Stx par l'administration d'une quantité thérapeutiquement efficace d'un tannin de bractée de houblon dérivé de Humulus lupulus. L'invention a également trait à des composés permettant l'isolement de composés de liaison à des molécules Stx, et des procédés permettant la détection de la présence de molécules Stx dans un échantillon biologique. Dans un mode de réalisation de l'invention, un sujet infecté d'une souche E.coli de production de Stx est traité par l'administration entérique d'une fraction de poids moléculaire élevé d'un extrait de bractée de houblon au sujet.
CA002498225A 2002-09-10 2003-09-09 Facteurs de liaison a des toxines bacteriennes Abandoned CA2498225A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40974202P 2002-09-10 2002-09-10
US60/409,742 2002-09-10
PCT/US2003/028282 WO2004024070A2 (fr) 2002-09-10 2003-09-09 Facteurs de liaison a des toxines bacteriennes

Publications (1)

Publication Number Publication Date
CA2498225A1 true CA2498225A1 (fr) 2004-03-25

Family

ID=31993998

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002498225A Abandoned CA2498225A1 (fr) 2002-09-10 2003-09-09 Facteurs de liaison a des toxines bacteriennes

Country Status (5)

Country Link
EP (1) EP1545209A4 (fr)
JP (1) JP2006508924A (fr)
AU (1) AU2003267079B2 (fr)
CA (1) CA2498225A1 (fr)
WO (1) WO2004024070A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087260A1 (fr) 2002-04-05 2003-10-23 University Of Massachusetts Lowell Antioxydants polymeres
CA2574588A1 (fr) 2004-07-23 2006-02-09 Polnox Corporation Macromonomeres et polymeres antioxydants, et leurs procedes de production et d'utilisation
CA2589855A1 (fr) 2004-12-03 2006-06-08 Polnox Corporation Processus pour la synthese d'antioxydants de polyalkylphenol
US7902317B2 (en) 2004-12-03 2011-03-08 Polnox Corporation Synthesis of aniline and phenol-based antioxidant macromonomers and corresponding polymers
WO2006091705A2 (fr) 2005-02-22 2006-08-31 Polnox Corporation Antioxydants macromoleculaires fonctionnels doubles contenant de l'azote et un phenol encombre: synthese, performances et applications
WO2006104957A2 (fr) 2005-03-25 2006-10-05 Polnox Corporation Antioxydants macromoleculaires alkyles et polymeres et procedes pour les produire et les utiliser
WO2006116532A2 (fr) 2005-04-28 2006-11-02 University Of Massachusetts Lowell Synthese d'oligo/poly(catechines) et methodes d'utilisation associees
WO2007050985A2 (fr) 2005-10-27 2007-05-03 Polnox Corporation Antioxydants macromoleculaires a base de phenols et de phosphites a encombrement sterique
US20070149660A1 (en) 2005-10-27 2007-06-28 Vijayendra Kumar Stabilized polyolefin compositions
WO2007064843A1 (fr) 2005-12-02 2007-06-07 Polnox Corporation Compositions d’huile lubrifiante
JP4431713B2 (ja) * 2006-03-07 2010-03-17 学校法人慶應義塾 コノフィリン及び／又はコノフィリジンの水溶液
WO2008005358A2 (fr) 2006-07-06 2008-01-10 Polnox Corporation Antioxydants macromoléculaires innovants comprenant des fragments antioxydants différents : structures, procédés de fabrication et d'utilisation
US7767853B2 (en) 2006-10-20 2010-08-03 Polnox Corporation Antioxidants and methods of making and using the same
JP2012153659A (ja) * 2011-01-27 2012-08-16 Akita Univ ホップ葉抽出物およびその製造方法
JP6232177B2 (ja) * 2011-11-28 2017-11-15 花王株式会社 ベロ毒素不活性化剤
WO2015077635A2 (fr) 2013-11-22 2015-05-28 Polnox Corporation Antioxydants macromoléculaires basés sur deux types de fractions par molécule : structures, leurs procédés de fabrication et d'utilisation
WO2018160879A2 (fr) 2017-03-01 2018-09-07 Polnox Corporation Structures d'inhibiteurs de corrosion macromoléculaire (mcin), leurs procédés de fabrication et d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2986805B2 (ja) * 1989-05-19 1999-12-06 三井農林株式会社 細菌性外毒素に対する抗毒素剤
US6251461B1 (en) * 1997-10-10 2001-06-26 S. S. Steiner, Inc. Antimicrobial activity of hops extract against Clostridium botulinum, Clostridium difficile and Helicobacter pylori
AU2440499A (en) * 1999-02-15 2000-08-29 Nikka Whisky Distilling Co., Ltd., The Adp-ribosylation inhibitors and remedies for endotoxic bacterial enteric infection containing proanthocyanidin as the active ingredient
JP2000342192A (ja) * 1999-06-08 2000-12-12 Natl Fedelation Of Agricult Coop Assoc 浮腫病対策用飼料
JP2001249134A (ja) * 1999-12-28 2001-09-14 Matsushita Electric Ind Co Ltd タンパク質濃度計測用試薬、これを用いたタンパク質濃度計測方法および尿検査方法
JP4521703B2 (ja) * 2000-05-17 2010-08-11 アサヒビール株式会社 ホップより得られるリパーゼ阻害剤

Also Published As

Publication number Publication date
WO2004024070A2 (fr) 2004-03-25
AU2003267079B2 (en) 2008-08-14
WO2004024070A3 (fr) 2004-08-05
EP1545209A4 (fr) 2009-07-29
JP2006508924A (ja) 2006-03-16
AU2003267079A1 (en) 2004-04-30
EP1545209A2 (fr) 2005-06-29

Similar Documents

Publication Publication Date Title
AU2003267079B2 (en) Factors that bind intestinal toxins
Ghosh et al. Targeted antibiotic delivery: selective siderophore conjugation with daptomycin confers potent activity against multidrug resistant Acinetobacter baumannii both in vitro and in vivo
Mühlen et al. Anti-virulence strategies to target bacterial infections
Möllmann et al. Siderophores as drug delivery agents: application of the “Trojan Horse” strategy
Gorityala et al. Hybrid antibiotic overcomes resistance in P. aeruginosa by enhancing outer membrane penetration and reducing efflux
Cano et al. State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections
Boukerb et al. Antiadhesive properties of glycoclusters against Pseudomonas aeruginosa lung infection
AlMatar et al. Efflux pump inhibitors: new updates
Ball et al. Conjugating berberine to a multidrug resistance pump inhibitor creates an effective antimicrobial
Renau et al. Inhibitors of efflux pumps in pseudomonas a eruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin
Birhanu et al. Inhibition of Salmonella Typhimurium adhesion, invasion, and intracellular survival via treatment with methyl gallate alone and in combination with marbofloxacin
Bahamondez-Canas et al. PEGylation of tobramycin improves mucus penetration and antimicrobial activity against Pseudomonas aeruginosa biofilms in vitro
Legros et al. Shiga toxin-glycosphingolipid interaction: Status quo of research with focus on primary human brain and kidney endothelial cells
Zhao et al. Bioinspired heteromultivalent ligand-decorated nanotherapeutic for enhanced photothermal and photodynamic therapy of antibiotic-resistant bacterial pneumonia
Lee et al. Shiga toxins induce autophagy leading to differential signalling pathways in toxin‐sensitive and toxin‐resistant human cells
Boyce et al. Platform to discover protease-activated antibiotics and application to siderophore–antibiotic conjugates
Li et al. Synthesis and assessment of globotriose–chitosan conjugate, a novel inhibitor of Shiga toxins produced by Escherichia coli
Sharaf et al. Preparation, urease inhibition mechanisms, and anti-Helicobacter pylori activities of hesperetin-7-rhamnoglucoside
Taouai et al. Glycocluster tetrahydroxamic acids exhibiting unprecedented inhibition of Pseudomonas aeruginosa biofilms
Wang et al. Design and Synthesis of 3-Hydroxy-pyridin-4 (1 H)-ones–Ciprofloxacin Conjugates as Dual Antibacterial and Antibiofilm Agents against Pseudomonas aeruginosa
Zahorska et al. Neutralizing the impact of the virulence factor LecA from Pseudomonas aeruginosa on human cells with new glycomimetic inhibitors
JP2021073278A (ja) 抗生物質として有用なコロルマイシン誘導体
WO1998026662A1 (fr) Composes et methodes pour traiter et prevenir les maladies bacteriennes et virales
WO1998026662A9 (fr) Composes et methodes pour traiter et prevenir les maladies bacteriennes et virales
Sinclair et al. Sialyloligosaccharides inhibit cholera toxin binding to the GM1 receptor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20100909